|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-9-25
|
|
pubmed:abstractText |
Hyperlipidemia associated with the protease inhibitor (PI) component of highly active antiretrovial treatment can lead to accelerated atherosclerosis. The apolipoprotein A-V (APOA5) gene, which affects VLDL production and lipolysis, may play a role in PI-induced hyperlipidemia, particularly in individuals with the APOA5-1131T-->C genotype.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0009-9147
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1914-9
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16887900-Apolipoproteins,
pubmed-meshheading:16887900-Apolipoproteins A,
pubmed-meshheading:16887900-Female,
pubmed-meshheading:16887900-Genetic Predisposition to Disease,
pubmed-meshheading:16887900-Genetic Variation,
pubmed-meshheading:16887900-HIV Infections,
pubmed-meshheading:16887900-HIV Protease Inhibitors,
pubmed-meshheading:16887900-Humans,
pubmed-meshheading:16887900-Hyperlipidemias,
pubmed-meshheading:16887900-Lipids,
pubmed-meshheading:16887900-Longitudinal Studies,
pubmed-meshheading:16887900-Male
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.
|
|
pubmed:affiliation |
Institut de Recerca en Ciències de la Salut, Hospital Universitari de Sant Joan de Reus, Universitat Rovira i Virgili, Reus, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
